TY  - JOUR
AU  - Ceccon, Garry
AU  - Lazaridis, Lazaros
AU  - Stoffels, Gabriele
AU  - Rapp, Marion
AU  - Weber, Manuel
AU  - Blau, Tobias
AU  - Lohmann, Phillip
AU  - Kebir, Sied
AU  - Herrmann, Ken
AU  - Fink, Gereon R.
AU  - Langen, Karl-Josef
AU  - Glas, Martin
AU  - Galldiks, Norbert
TI  - Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience
JO  - European journal of nuclear medicine and molecular imaging
VL  - 45
IS  - 9
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - FZJ-2018-02172
SP  - 1626 - 1635
PY  - 2018
AB  - PurposeWe present our first clinical experience with O-(2-18F-fluoroethyl)-l-tyrosine (FET) PET in patients with high-grade glioma treated with various neurooncological therapies including tumour-treating fields (TTFields) for the differentiation of tumour progression from treatment-related changes.MethodsWe retrospectively assessed 12 patients (mean age 51 ± 12 years, range 33–72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes. Mean and maximum tumour-to-brain ratios (TBRmean, TBRmax) were calculated. The definitive diagnosis (tumour progression or posttherapeutic changes) was confirmed either by histopathology (4 of 12 patients) or on clinical follow-up.ResultsIn all nine patients with confirmed tumour progression, the corresponding FET PET showed increased uptake (TBRmax 3.5 ± 0.6, TBRmean 2.7 ± 0.7). In one of these nine patients, FET PET was consistent with treatment-related changes, whereas standard MRI showed a newly diagnosed contrast-enhancing lesion. In two patients treated solely with TTFields without any other concurrent neurooncological therapy, serial FET PET revealed a decrease in metabolic activity over a follow-up of 6 months or no FET uptake without any signs of tumour progression or residual tumour on conventional MRI.ConclusionFET PET may add valuable information in monitoring therapy in individual patients with high-grade glioma undergoing neurooncological treatment including TTFields.
LB  - PUB:(DE-HGF)16
C6  - pmid:29564490
UR  - <Go to ISI:>//WOS:000437733300016
DO  - DOI:10.1007/s00259-018-3992-5
UR  - https://juser.fz-juelich.de/record/844796
ER  -